Literature DB >> 21726996

Immuno-imaging using nanobodies.

Ilse Vaneycken1, Matthias D'huyvetter, Sophie Hernot, Jens De Vos, Catarina Xavier, Nick Devoogdt, Vicky Caveliers, Tony Lahoutte.   

Abstract

Immuno-imaging is a developing technology that aims at studying disease in patients using imaging techniques such as positron emission tomography in combination with radiolabeled immunoglobulin derived targeting probes. Nanobodies are the smallest antigen-binding antibody-fragments and show fast and specific targeting in vivo. These probes are currently under investigation as therapeutics but preclinical studies indicate that nanobodies could also become the next generation of magic bullets for immuno-imaging. Initial data show that imaging can be performed as early as 1 hour post-injection enabling the use of short-lived radio-isotopes. These unique properties should enable patient friendly and safe imaging protocols. This review focuses on the current status of radiolabeled nanobodies as targeting probes for immuno-imaging.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21726996     DOI: 10.1016/j.copbio.2011.06.009

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   9.740


  44 in total

Review 1.  Molecular engineering of antibodies for therapeutic and diagnostic purposes.

Authors:  Frédéric Ducancel; Bruno H Muller
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

2.  Specific targeting of atherosclerotic plaques in ApoE(-/-) mice using a new Camelid sdAb binding the vulnerable plaque marker LOX-1.

Authors:  Jens De Vos; Iris Mathijs; Catarina Xavier; Sam Massa; Ulrich Wernery; Luc Bouwens; Tony Lahoutte; Serge Muyldermans; Nick Devoogdt
Journal:  Mol Imaging Biol       Date:  2014-10       Impact factor: 3.488

3.  Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo.

Authors:  David Maussang; Azra Mujić-Delić; Francis J Descamps; Catelijne Stortelers; Peter Vanlandschoot; Marijke Stigter-van Walsum; Henry F Vischer; Maarten van Roy; Maria Vosjan; Maria Gonzalez-Pajuelo; Guus A M S van Dongen; Pascal Merchiers; Philippe van Rompaey; Martine J Smit
Journal:  J Biol Chem       Date:  2013-08-26       Impact factor: 5.157

Review 4.  The Immunoimaging Toolbox.

Authors:  Aaron T Mayer; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2018-05-24       Impact factor: 10.057

Review 5.  Nanodrug delivery systems: a promising technology for detection, diagnosis, and treatment of cancer.

Authors:  Anish Babu; Amanda K Templeton; Anupama Munshi; Rajagopal Ramesh
Journal:  AAPS PharmSciTech       Date:  2014-02-19       Impact factor: 3.246

6.  131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment.

Authors:  Matthias D'Huyvetter; Jens De Vos; Catarina Xavier; Marek Pruszynski; Yann G J Sterckx; Sam Massa; Geert Raes; Vicky Caveliers; Michael R Zalutsky; Tony Lahoutte; Nick Devoogdt
Journal:  Clin Cancer Res       Date:  2017-07-27       Impact factor: 12.531

7.  Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains.

Authors:  Karl R Schmitz; Atrish Bagchi; Rob C Roovers; Paul M P van Bergen en Henegouwen; Kathryn M Ferguson
Journal:  Structure       Date:  2013-06-20       Impact factor: 5.006

8.  In situ proteolysis, crystallization and preliminary X-ray diffraction analysis of a VHH that binds listeria internalin B.

Authors:  Ian Huh; Robert Gene; Jyothi Kumaran; C Roger MacKenzie; Cory L Brooks
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2014-10-25       Impact factor: 1.056

9.  New applications of nanotechnology for neuroimaging.

Authors:  G Suffredini; J E East; L M Levy
Journal:  AJNR Am J Neuroradiol       Date:  2013-03-28       Impact factor: 3.825

10.  Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding.

Authors:  Kendra N Iskander; Marcin F Osuchowski; Deborah J Stearns-Kurosawa; Shinichiro Kurosawa; David Stepien; Catherine Valentine; Daniel G Remick
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.